Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Cash & Current Investments (2016 - 2025)

Orthofix Medical (OFIX) has disclosed Cash & Current Investments for 16 consecutive years, with $85.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 0.73% year-over-year to $85.1 million, compared with a TTM value of $85.1 million through Dec 2025, down 0.73%, and an annual FY2025 reading of $85.1 million, down 0.73% over the prior year.
  • Cash & Current Investments was $85.1 million for Q4 2025 at Orthofix Medical, up from $65.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $94.6 million in Q1 2021 and bottomed at $28.9 million in Q2 2024.
  • Average Cash & Current Investments over 5 years is $59.7 million, with a median of $60.0 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments plummeted 53.75% in 2021, then skyrocketed 137.96% in 2025.
  • Year by year, Cash & Current Investments stood at $87.8 million in 2021, then tumbled by 42.29% to $50.7 million in 2022, then fell by 25.53% to $37.8 million in 2023, then soared by 127.08% to $85.7 million in 2024, then dropped by 0.73% to $85.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for OFIX at $85.1 million in Q4 2025, $65.9 million in Q3 2025, and $68.7 million in Q2 2025.